Showing 541 - 560 results of 99,895 for search '(( 5 ((026 decrease) OR (a decrease)) ) OR ( 5 ((nn decrease) OR (we decrease)) ))', query time: 1.61s Refine Results
  1. 541
  2. 542
  3. 543
  4. 544

    The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial by Ma Somsouk (283498)

    Published 2014
    “…<div><p>The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. …”
  5. 545

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    “…However, there is concern that by neutralizing the SARS-CoV-2 virus, nMAbs may decrease the availability of antigens to the immune system, potentially impairing the endogenous polyclonal immune response and decreasing long-term immune protection.…”
  6. 546
  7. 547
  8. 548

    S1 Data - by Jordan A. Gunning (18143970)

    Published 2024
    “…Specifically, total immune cells (CD45+) decrease at days 2 and 5 following IR, macrophages (F4/80+CD11b+) decrease at day 2 and 5 and increase at day 30, while neutrophils (Ly6G+CD11b+) significantly increase at day 30 following IR. …”
  9. 549

    C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion by Yunwei Shi (10116568)

    Published 2021
    “…Here, we determined whether C5aR1 signaling was essential to the post-ischemic inflammation and brain injury and whether it is a valid target for therapeutic blockade by using soluble receptor antagonist PMX53 in the early stage after I/R injury. …”
  10. 550

    C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion by Yunwei Shi (10116568)

    Published 2021
    “…Here, we determined whether C5aR1 signaling was essential to the post-ischemic inflammation and brain injury and whether it is a valid target for therapeutic blockade by using soluble receptor antagonist PMX53 in the early stage after I/R injury. …”
  11. 551

    C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion by Yunwei Shi (10116568)

    Published 2021
    “…Here, we determined whether C5aR1 signaling was essential to the post-ischemic inflammation and brain injury and whether it is a valid target for therapeutic blockade by using soluble receptor antagonist PMX53 in the early stage after I/R injury. …”
  12. 552

    C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion by Yunwei Shi (10116568)

    Published 2021
    “…Here, we determined whether C5aR1 signaling was essential to the post-ischemic inflammation and brain injury and whether it is a valid target for therapeutic blockade by using soluble receptor antagonist PMX53 in the early stage after I/R injury. …”
  13. 553

    C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion by Yunwei Shi (10116568)

    Published 2021
    “…Here, we determined whether C5aR1 signaling was essential to the post-ischemic inflammation and brain injury and whether it is a valid target for therapeutic blockade by using soluble receptor antagonist PMX53 in the early stage after I/R injury. …”
  14. 554
  15. 555
  16. 556
  17. 557

    SARS-CoV-2 genome sequencing metrics. by Ludy R. Carmola (20978107)

    Published 2025
    “…We investigated viral and host factors, including vaccination status, that were associated with SARS-CoV-2 disease severity in a setting with low vaccination rates. …”
  18. 558

    SARS-CoV-2 variants by vaccination status. by Ludy R. Carmola (20978107)

    Published 2025
    “…We investigated viral and host factors, including vaccination status, that were associated with SARS-CoV-2 disease severity in a setting with low vaccination rates. …”
  19. 559
  20. 560